Brevet Marie, Fucks David, Chatelain Denis, Regimbeau Jean-Marc, Delcenserie Richard, Sevestre Henri, Ouadid-Ahidouch Halima
Department of Pathology, CHU Amiens, France.
Pancreas. 2009 Aug;38(6):649-54. doi: 10.1097/MPA.0b013e3181a56ebf.
The aim of this study was to examine expression of 2 potassium (K) channels in pancreatic adenocarcinoma.
The immunohistochemical and mRNA expression of GIRK1 (G-protein inwardly rectifying K channel 1) and KV1.3 channel (voltage-dependent K channel) was studied in 55 and 18 adenocarcinomas and 33 and 8 normal pancreas specimens, respectively. The methylation status of KV1.3 promoter was studied by methyl-specific polymerase chain reaction in 33 pancreatic adenocarcinomas. The results were correlated with the patients' prognosis.
GIRK1 was highly expressed in 80% (44/55) of adenocarcinoma samples versus 57.6% (19/33) of normal samples (P=0.03), as confirmed by reverse transcriptase-polymerase chain reaction results (P=0.007). KV1.3 expression was decreased in pancreatic adenocarcinomas compared with normal tissue (7.3% vs 39.4%; P=0.0005). KV1.3 down-expression was associated with metastatic tumors (P=0.018). KV1.3 promoter methylation was observed in 69.7% (22/33) of adenocarcinomas.
This is the first report of deregulation of 2 K channels in pancreatic adenocarcinoma. GIRK1 was highly expressed in pancreatic adenocarcinomas, corresponding to its role in cell proliferation. Methylation of KV1.3 gene promoter could explain the decrease of KV1.3 expression in adenocarcinomas. New therapeutic agents, such as DNA methylation inhibitors, could be useful against this dramatic cancer.
本研究旨在检测两种钾(K)通道在胰腺腺癌中的表达情况。
分别在55例和18例腺癌以及33例和8例正常胰腺标本中研究了GIRK1(G蛋白内向整流钾通道1)和KV1.3通道(电压依赖性钾通道)的免疫组化及mRNA表达。通过甲基化特异性聚合酶链反应在33例胰腺腺癌中研究了KV1.3启动子的甲基化状态。结果与患者的预后相关。
逆转录聚合酶链反应结果证实,GIRK1在80%(44/55)的腺癌样本中高表达,而在正常样本中为57.6%(19/33)(P = 0.03)(P = 0.007)。与正常组织相比,胰腺腺癌中KV1.3表达降低(7.3%对39.4%;P = 0.0005)。KV1.3低表达与转移性肿瘤相关(P = 0.018)。在69.7%(22/33)的腺癌中观察到KV1.3启动子甲基化。
这是关于胰腺腺癌中两种钾通道失调的首次报道。GIRK1在胰腺腺癌中高表达,与其在细胞增殖中的作用相对应。KV1.3基因启动子的甲基化可以解释腺癌中KV1.3表达的降低。新的治疗药物,如DNA甲基化抑制剂,可能对这种严重的癌症有效。